Cidofovir

别名: HPMPC, GS 0504 中文名称：西多福韦

目录号：S1516 Purity: 99.89%

Cidofovir通过选择性抑制病毒DNA的合成而抑制病毒复制。

Cidofovir Chemical Structure

CAS: 113852-37-2

规格	价格	库存
25mg	811.35	现货
100mg	2198.16	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.89%

99.89

Cidofovir相关产品

相关靶点	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	点击展开
相关产品	Pidnarulex (CX-5461) SCR7 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) B02 BMH-21 YK-4-279 Bergapten Tegafur (FT-207) Azaguanine-8 Halofuginone Adenine HCl Mizoribine Cyclocytidine HCl Thymidine APX-3330 Nedaplatin 6-Thio-dG Flupirtine maleate JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin BC-LI-0186 CRT0044876 PFM01 Adenine ML216	点击展开
相关化合物库	FDA药物库天然产物库凋亡分子化合物库 DNA损伤/ DNA修复化合物库细胞周期化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	孵育时间	活性描述	文献信息
HEL cells	Function assay	3 days	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM	17961851
HEL cells	Function assay	3 days	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM	17961851
HFF	Proliferation assay	3 days	Antiproliferative activity against HFF after 3 days by coulter counter assay, EC50=1.9 μM	19029322
HeLaS3 cells	Function assay	3-5 days	Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay, EC50=18.74 μM	18852271
HSB2 cells	Function assay	7 days	Antiviral activity against Human herpesvirus 6 GS infected in human HSB2 cells assessed as decrease in viral DNA accumulation after 7 days, EC50=2.7 μM	19770274
HEL cells	Function assay		Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells, EC50=0.57 μM	14643328
MRC-5 cells	Function assay		Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells, IC50=10 μM	8632439
NHDF cells	Function assay		Inhibitory activity against replication of HCMV in NHDF cells, IC50=0.5 μM	8632439
HFF cells	Function assay		Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity, EC50=3.2 μM	16603351
HFF cells	Function assay		Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity, EC50=7.1 μM	16603351
HFF cells	Function assay		Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells, EC50=6.9 μM	16722657
bone marrow cells	Cytotoxicity assay		Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50=10 μM	16814545
HFF cells	Function assay		Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50=0.3 μM	17043128
MRC5 cells	Function assay		Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50=0.3 μM	17043128
UC1B cells	Function assay		Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity, EC50=13 μM	17420214
african green monkey Vero cells	Function assay		Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=14.4 μM	17438061
HFF cells	Function assay		Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50=0.22 μM	17709468
HEL cells	Function assay		Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.74 μM	19226140
HEL cells	Function assay		Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.5 μM	19226140
HEL cells	Function assay		Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.3 μM	19226140
HEL cells	Function assay		Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, IC50=0.045 μM	19226140
A549 cells	Function assay		Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay, EC50=16.5 μM	20585112
HFF cells	Function assay		Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50=6.7 μM	21376429
点击查看更多细胞系数据

生物活性

产品描述	Cidofovir通过选择性抑制病毒DNA的合成而抑制病毒复制。

体外研究(In Vitro)
体外研究活性	Cidofovir处理培养的细胞，抑制人类巨细胞病毒（HCMV）感染。Cidofovir抑制巨细胞病毒（CMV）蚀斑形成，即使是感染后48小时后加入到细胞中，作用于Davis和AD-169株时IC50分别为0.9 μg/mL和1.6 μg/mL。^[1] Cidofovir也抑制单纯疱疹病毒感染。此外，Cidofovir作用于猴肾细胞，抑制HSV-1诱导的细胞融合，也抑制HSV-1特异性蛋白的表达和病毒DNA的合成。^[3]

体内研究(In Vivo)
体内研究活性	Cidofovir 每天按5 mg/kg剂量皮下注射给药受感染的豚鼠，持续给药5天，显著降低血，脾，肺，和唾液腺中病毒传染力。Cidofovir处理受感染的动物，显著降低淋巴细胞增多和脾脏的平均组织指数。^[2] Cidofovir作用于皮内感染与HSV-1或HSV-2的无毛小鼠，抑制所有临床表现（皮肤损伤，后腿瘫痪，和死亡）。Cidofovir最显着的特点是感染后到直至第4天才单独给药，也显著抗HSV-1或HSV-2感染。^[4] Cidofovir作用于皮下移植小鼠黑色素瘤B16细胞的C57B16/J小鼠，抑制产生的高度侵袭性的黑色素瘤的生长。^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04542252	Completed	Drug Drug Interaction	SymBio Pharmaceuticals	November 9 2020	Phase 1
NCT01610765	Withdrawn	Herpes Simplex Virus	University of Alabama at Birmingham	January 2016	Phase 1\|Phase 2
NCT01816646	Completed	Blood And Marrow Transplantation	M.D. Anderson Cancer Center\|Gilead Sciences	September 2013	Phase 1
NCT00780182	Completed	Healthy	Chimerix\|National Institutes of Health (NIH)	October 2008	Phase 1

参考文献
[1] Snoeck R, et al, Antimicrob Agents Chemother, 1988, 32(12), 1839-1844. [2] Li SB, et al. Antiviral Res, 1990, 13(5), 237-252. [3] Chatterjee S, et al. Antiviral Res., 1992, 19(3), 181-192. [4] De Clercq E, et al. Antimicrob Agents Chemother, 1991, 35(4), 701-706. [5] Redondo P, et al. Br J Dermatol, 2000, 143(4), 741-748. + 展开

参考文献

+ 展开

化学信息&溶解度

分子量	279.19	分子式	C₈H₁₄N₃O₆P
CAS号	113852-37-2	SDF	Download Cidofovir SDF
Smiles	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

Water : 5 mg/mL (17.9 mM)

DMSO : Insoluble ( ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : Insoluble

Water : 7 mg/mL (25.07 mM)

DMSO : Insoluble ( ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : Insoluble

Water : 12 mg/mL (42.98 mM)

DMSO : 2 mg/mL ( (7.16 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : Insoluble

Water : 7 mg/mL (25.07 mM)

DMSO : 0.005 mg/mL ( (0.01 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Cidofovir

产品质控

Cidofovir相关产品

相关信号通路图

细胞实验数据示例

生物活性

化学信息&溶解度

实验计算

技术支持